These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35852704)

  • 1. Predictors of Small Bowel Obstruction Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Jedrzejko N; Wong A; MacNeill AJ; Hamilton TD
    J Gastrointest Surg; 2022 Oct; 26(10):2176-2183. PubMed ID: 35852704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.
    Turner KM; Morris MC; Delman AM; Hanseman D; Johnston FM; Greer J; Walle KV; Abbott DE; Raoof M; Grotz TE; Fournier K; Dineen S; Veerapong J; Maduekwe U; Kothari A; Staley CA; Maithel SK; Lambert LA; Kim AC; Cloyd JM; Wilson GC; Sussman JJ; Ahmad SA; Patel SH
    J Gastrointest Surg; 2022 Dec; 26(12):2569-2578. PubMed ID: 36258061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of primary tumor origin in gastrointestinal malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Leigh N; Solomon D; Pletcher E; Labow DM; Magge DR; Sarpel U; Golas BJ
    World J Surg Oncol; 2020 Jul; 18(1):182. PubMed ID: 32703239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
    Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
    Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    Clin Interv Aging; 2021; 16():559-568. PubMed ID: 33833505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit.
    Bhutiani N; Grotz TE; Concors SJ; White MG; Helmink BA; Raghav KP; Taggart MW; Beaty KA; Royal RE; Overman MJ; Matamoros A; Scally CP; Rafeeq S; Mansfield PF; Fournier KF
    Ann Surg Oncol; 2024 Jan; 31(1):614-621. PubMed ID: 37872456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix.
    Lopez-Ramirez F; Gushchin V; Sittig M; King MC; Baron E; Nikiforchin A; Nieroda C; Sardi A
    Ann Surg Oncol; 2022 Jun; 29(6):3390-3401. PubMed ID: 35133518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms.
    Valenzuela CD; Mangieri CW; Garland-Kledzik M; Gawdi R; Russell G; Perry KC; Votanopoulos KI; Levine EA; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3422-3431. PubMed ID: 35254575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.